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interstitial brachytherapy (BRT) in the anal canal based on RM 
guidance. 
Materials and Methods: After a month from the end of the combined 
treatment RTCT, all the patients got a clinical examination, a PET-CT 
and a MRI. The prescribed brachytherapy target volume (TV) was 
individuated, supported by a radiologist, by MRI performed with 
vaginal applicator (MRI compatible) positioned in the anus. With a 
MUPIT applicator (Elekta©) in situ a CT simulation was performed. CT 
images were fused with MRI by deformable co-registration 
(Velocity©). A treatment pre-plan was created in order to have 
information on the optimal position of the needles. Then the needles 
were positioned according to the indications of the pre-treatment 
plan. Afterward the patient underwent again a CT scan and the 
definitive treatment plan was created on Oncentra Brachy© console. 
Results: From February to June 2012, we treated 4 patients. 3 
patients had histological diagnosis of squamous cell anal canal 
carcinoma (SCACC), instead 1 patient was a low rectum 
adenocarcinoma. The median age was 61,5 (range 49-78). There were: 
2 patients cT2N0M0, 1 patient cT4N0M0 and1 patient cT4N2M0. A 
patient didn't ultimate the RT-CT combined treatment for toxicity. No 
complications were observed during and after the implant. The early 
follow up indicates no episodes of common complications at the first 
follow-up. Three patients had a complete response without tumor 
evidence and were alive without local recurrence or metastases. The 
patient that didn't ultimate RT-CT treatment had a local persistance. 
The dosimetric analysis showed that the mean TV was 16,03 cc and 
the mean TV covered by almost 100% of dose was 14.73 cc. The mean 
percentage of TV covered by less than 100% of dose was 4,9%. 
Conclusions: The integration of MRI guidance in BRT procedures 
seems to offer a better evaluation of the pelvis district adapting plan 
of treatment at the TV. Patients had a good compliance and no 
episodes of complication for now. To evaluate the clinical results in 
terms of local control and survival we need a longer follow up and a 
more representative sample. 
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Purpose/Objective: The first treatments with INTRABEAM ® system 
(Carl Zeiss SAS) using low energy X-rays were performed in our 
institution in October 2011. Between 2004 and 2011 an electron linear 
accelerator was used for intraoperative irradiation of the breast for 82 
patients. 
Materials and Methods: Fifty-nine patients of mean age 71 years [59-
87] have now been treated with INTRABEAM ®. For each, the radiation 
dose required was 20 Gy to the surface of the surgical margin in a 
single fraction. With the linear accelerator, 21 Gy were prescribed to 
the 90% depth dose of the chosen energy. The system INTRABEAM ® 
produces low energy photons from a 50 kV and 40μA source while 
preceding irradiation technique used electrons energy of 6 or 9 MeV. 
The isotropy of the low energy photon beam and the dose rate were 
measured before each treatment with a specific system and a 
calibrated ionization chamber. During irradiation with electrons, we 
realized an 'in vivo' measurement with a semiconductor placed at the 
tumor bed by the surgeon and the radiotherapist during the 
positioning of the applicator. With the new technique, sterile 
applicators with variable diameters from 3 to 5 cm are selected to 
exactly fit the surgical cavity, thus allowing a homogeneous spherical 
irradiation. In our previous technique, the tumor bed 'flattened' was 
systematically located 2 cm from the edge of the applicator (4 to 6 
cm in diameter) to get a sufficient safety margin for processing. 
Results: With INTRABEAM ®, the dose attenuation is rapid (5.4 Gy at 1 
cm from the applicator surface), thereby reducing damage to 
surrounding healthy tissue. For treatment, mobile system is installed 
in one of two operating ambulatory surgery designed in accordance 
with radiation protection standards and does not require as before the 
immobilization of a radiotherapy bunker. The average time needed to 
deliver the dose was 27 minutes [20-53] for 59 patients using the low 
energy photon technique. This time depends on the size of the 
applicator and is longer than the 11 minutes used before to deliver 
the prescribed dose with electrons. However, the total time needed 
for the room and the staff is not more important with INTRABEAM ® 
system as before. 
Conclusions: The shift from breast intraoperative radiotherapy using a 
linear accelerator to INTRABEAM® was realized with no major 
problems in our institution. Using this new system has improved the 
workflow of radiotherapy and surgery, and thus increases the number 
of patients that can benefit from this technique. 
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Purpose/Objective: In the last ten years, intraoperative radiotherapy 
has been used extensively in the clinical setting as the exclusive mode 
of partial breast irradiation or as tumor bed boost during BCS. A 
careful diagnostic evaluation is essential for the choice of the most 
appropriate treatment. Most international guidelines recommend a 
multidisciplinary approach for patients with breast cancer. The 
multidisciplinary team provide to establish quality standards in the 
multiple aspects of the treatment and may be particularly important 
for a procedure as IORT in which different professionals must work 
together for the successful implementation of the treatment. 
Materials and Methods: In our center, since February 2005 we treated 
about 500 cases of breast cancer with IORT and since January 2011, 
all patients were evaluated by the multidisciplinary team made up of 
surgeon, radiologist, radiation oncologist, medical oncologist, 
pathologist, radiographers and nurses. The selection of patients to be 
able to be submitted to IORT exclusively takes place, in agreement 
with the surgeon, on the basis of the ASTRO guidelines, all other 
patients are treated with EBRT and intraoperative boost. One of the 
main limitations in the use of IORT is the absence of pathology 
information; in our center all patients received core-biopsy with the 
evaluation of predictive parameters (histology, grading, Her2, ER, 
PgR, Ki67). During the surgery extemporaneous histological 
examination is performed to evaluate the surgical margins and the 
sentinel lymph node. 
Results: Since January 2011 to October 2012 in our hospital 152 
patients were treated with BCS and IORT. All patients were evaluated 
by the multidisciplinary team before and after surgery.  
37 patients, had a biopsy compliant with the ASTRO criteria and 
received IORT exclusively, 115 received anticipated boost. 
Histologically, three patients treated with IORT exclusive, were not 
fully compliant with the ASTRO criteria: in one case there was 
evidence of neoplastic thrombus in the sentinel node, in the other 
case the grading was 3 and in the last case it was a lobular form. 
Conclusions: An integrated, multidisciplinary approach is desiderable 
to treat all patients. We consider IORT a safe procedure, with good 
cosmetic results, allowing more women to have access to breast 
conserving therapy; a careful selection of patients who may benefit 
from a partial breast irradiation is needed. We believe that the core- 
biopsy examination can be very predictive and therefore mandatory 
before an exclusive treatment.The close and constant collaboration 
with the surgeon and the pathologist has been essential in the 
improvement of the entire procedure. 
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Purpose/Objective: The use of low energy X-ray radiotherapy is not 
always done in ideal conditions with the beam perpendicular to the 
surface. It is therefore important to know what will be the impact of 
the angle made by the applicator on the dose distribution. For this we 
have developed a software based on a Monte Carlo code. 
Materials and Methods: We use a papillon50 emitting 50 kV X-ras with 
applicators of different diameters (22, 25 and 30 mm). The apparatus 
and applicators were modeled with the Monte Carlo code PENELOPE. 
The validation of this model was made by comparing calculations and 
measurements by ionization chamber and films gafchromics EBT2. It 
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was then possible to develop software for calculating the dose 
distribution at any angle made of the applicator with the surface. 
Results: The software calculates the dose distribution by varying the 
angle and the depth to which you want to know. The variation of 
homogeneity is very important. For an angle of 25°, the 
inhomogeneity in the surface plane is between 100 and 40 %. 
Conclusions: A software has been developed, based on the 
computation code PENELOPE to know the dose distribution at any 
depth as a function of angle applicator with the surface. 
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Purpose/Objective: IORT is becoming an increasingly popular 
approach for cancer treatment. Especially patients with very close or 
positive margins after resection or recurrent cancer benefit from 
IORT. For situations where a flat area (up to 6cm in diameter) has to 
be treated intraoperatively, new applicators for superficial treatment 
with a miniature x-ray source (INTRABEAM® System, Carl Zeiss Surgical 
GmbH, Oberkochen, Germany) were developed. They were evaluated 
using ionization chamber and film dosimetry. 
Materials and Methods: Each of the so called FLAT (1 – 6cm diameter) 
and SURFACE Applicators (1cm – 4cm diameter) consists of a radiation 
protective metal tube and a flattening filter, which converts the 
spherical dose distribution of the x-ray source into a flat one. The 
homogeneity of each dose distribution and depth dose measurements 
were evaluated using film dosimetry (Gafchromic EBT2 films, ISP, New 
Jersey, USA) in a solid water phantom (Gammex 457, Gammex Inc., 
Middleton, WI, USA) and a soft x-ray ionization chamber (Type 34013, 
PTW, Freiburg, Germany) in a water tank (Carl Zeiss Surgical GmbH, 
Oberkochen, Germany). 
Results: The FLAT Applicators show the best homogeneity, with a 
maximum standard deviation of 2.66%, in certain depths. In 1mm 
depth SURFACE Applicators show a lower field edge dose (compared to 
the central axis dose) of up to 31%, which corresponds to a 
geometrical error of 2mm. They also show a higher dose rate (0.53 -
1.78Gy/min in 5mm depth) and a steeper dose gradient compared to 
the FLAT Applicators (0.17 – 1.24Gy/min in 5mm depth). This results 
in a treatment time of 1.0 – 6.5min in an instance of a prescription of 
10Gy to the surface of the SURFACE Applicators, respectively 9.5 – 
61min in case of a prescription of 10Gy in 5mm depth from the surface 
of the FLAT Applicators. 
Conclusions: Generating flat dose distributions in a certain depth 
using the INTRABEAM® System and novel applicators result in an 
inhomogeneity at the surface of these applicators. To evaluate the 
exact extent of homogeneity there, further research based on Monte 
Carlo simulation is needed. But the results show that it is possible to 
perform a superficial localized IORT with shielding of the surrounding 
tissue and with minimum radiation protection requirements. 
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Purpose/Objective: A new method for in vivo dosimetry (IVD) during 
breast intraoperative radiation therapy (IORT) was carried out to 
improve informations on the dose actually delivered to the target and 
on the alignment of the shielding disk. With this method it is possible 
to acquire two bi-dimensional dose distributions: one just below the 
target and the other beyond the shielding disk.  
Materials and Methods: Breast IORT requires the protection of the 
tissues underneath the target volume. This is achieved by the surgeon 
positioning a shielding disk between the residual breast and the 
pectoralis fascia. The position of the disk is a very suitable location 
for performing IVD. In our experience we prepared two layers of 
radiochromic films, Gafchromic® EBT3 of the same size of the 
shielding disk, we fixed them by sterile tape to both sides of the disk, 
which was then delivered to the surgeon for subsequent placement. 
The gafchromic films were calibrated in dose for the two energy (6 
and 9 MeV) usually employed in breast cancer treatment to provide a 
bi-dimensional distribution in term of absolute dose. After each 
treatment the radiochromic films were read by a CCD scanner 
producing two digital images suitable for subsequent analysis. 
Results: The Department of Radiotherapy of Trieste has recently 
implemented a IORT dedicated electron-beam accelerator, the 
Intraop® Mobetron. The first patients were treated immediately after 
conservative surgery for breast carcinoma, and two in vivo dose maps 
were acquired for all of them. The image related to the film 
positioned on top of the disk allowed us to evaluate the mean 
absolute dose in a central area of the exposed field to compare with 
the prescribed dose. In all cases we obtained excellent agreement. 
The uniformity of the exposed area was also evaluated (Fig.1). 
  
 
Fig.1 – Images of the EBT3 Gafchromic® film located on the upper face 
of the shielding disk. a) Original image (green channel); b) 
Representation enhancing the dishomogeneities of the target. 
From the image related to the lower film position we were able to 
measure the dose that actually crosses the shielding. We employed 
new shielding disks provided by IntraOp® company, made by stacking a 
5 mm perspex layer, a 3 mm copper layer and 2 mm perspex layer. 
With these disks we always measured negligible transmission values. 
Geometrical analysis of the position of the exposed area can provide 
information about the extent of the unavoidable misalignment 
between the treatment field and the protective disk. In this way it is 
possible to evaluate the amount of dose that escapes from the 
shielding and that provides undesirable dose to healthy tissues. 
Conclusions: High dose IORT treatment requires high accuracy. For 
this reason IVD represents a very important test to evaluate the actual 
delivered dose. Gafchromic® EBT3 film prooves an effective and 
appropriate dosimeter to be surgically applied to the patient. The 
absolute dose measurement provides verification of the correct 
exposure to the target, as well as an estimation of the dose to the 
healthy tissue. 
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Purpose/Objective: To evaluate the local control and early late 
toxicity of IORT for localized prostate cancer. 
Materials and Methods: Between December 2009 and September 
2010, 8 patients with locally advanced prostate cancer or high 
local/systemic relapse risk were selected. We enrolled patients with ≤ 
70 years age, without clinical nodal disease, and at least two of 
following characteristics: pre-operative PSA >10 ng/ml and <20ng/ml; 
Gleason score ≥7; cT2c; or at least one of following characteristics: 
apical gland involved; pre-operative PSA >20ng/ml and <50ng/ml; 
Gleason score ≥8; cT≥3. Before the surgery the Ethical Board validated 
informed consent for adjuvant IORT was obtained. The surgery 
included radical prostatectomy with iliac-obturator lymphadenectomy 
and extemporaneous histological examination for nodal metastasis 
research. After prostate removal the patients were irradiated with 
IORT receiving a radical dose of 20 Gy in single fraction by 10 MeV 
electron beam. The IORT procedure was performed after bladder-
urethral anastomosis and confirmation of pathological negativity of 
